Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print      Mail a friend

Wednesday 27 June, 2018

PureTech Health PLC

Additional Listing

RNS Number : 6797S
PureTech Health PLC
27 June 2018

PureTech Health plc

Block listing Application

PureTech Health plc ("PureTech Health" or "the Group") (LSE: PRTC) announces that an application has been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for a block listing of 250,000 ordinary shares of 1 pence each (the "Ordinary Shares").

The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the PureTech Performance Share Plan.

It is expected that admission of the Ordinary Shares will become effective on 29 June 2018. The Ordinary Shares will rank pari passu in all respects with the Group's existing ordinary shares in issue.

About PureTech Health

PureTech Health (PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the "BIG" axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, PureTech Health is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline of innovative therapies that includes two pivotal stage programmes, multiple human proof-of-concept studies and a number of early clinical and pre-clinical programmes. PureTech's research and development pipeline has been advanced in collaboration with some of the world's leading scientific experts, who along with PureTech's team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. For more information, visit or connect with us on Twitter @puretechh.




Allison Mead Talbot

+1 617 651 3156

[email protected]


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t